AI주식인사이트AI Stock Insight
C

와이바이오로직스

338840KOSDAQ자연과학 및 공학 연구개발업

40.4 / 100

Reference Date: 2026-06-10

Financial Score10.5 / 40
News Sentiment16.9 / 25
Momentum3.0 / 20
Disclosure10.0 / 15
AI Analysis: the high debt ratio poses financial risk, PBR raises overvaluation concerns. Plunged 35.7% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

WaiBioLogics is a biopharmaceutical company developing advanced antibody-based therapies, including immune checkpoint inhibitors, ADCs, and bispecific antibodies, leveraging its proprietary discovery platform. Key pipelines include YBL-006, AR166, AR169, and AR170, with revenue generated through technology licensing and contract research services.

Number of Employees

58people

Average Salary

60.4M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 62.704.0Point
PBR
7.88Industry Average 3.240.0Point

2.4x industry avg (risky)

ROE
-186.97Industry Average -32.093.5Point

5.8x industry avg (excellent)

Debt Ratio
105.13Industry Average 7.310.0Point

14.4x industry avg (risky)

Trend 2023~20253.0 / 10 points
Revenue Growth Rate
2.0 / 3

Avg ▲8.1% (2-year basis)

Operating Profit Growth Rate
1.0 / 3

Avg ▲3.5% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -111.6% (declining, 3yr)

Detailed News Sentiment

2 totalPositive 1Neutral 1Negative 0Average Sentiment Score 67.5

Detailed Momentum

52-week position1.0Point

Near 52w low (17%, downtrend)

Current 13,640Won52-week high 35,60052-week low 9,030
1-month return0.0Point

1m -35.66% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-04
  • Neutral주주명부폐쇄기간또는기준일설정2026-05-27
  • Neutral주주총회소집결의 (임시주주총회)2026-05-27
  • Neutral임시주주총회결과2026-05-19
  • Neutral분기보고서 (2026.03)2026-05-15